JEA BizDev Consulting, LLC®

Find your next opportunity.

HomeConnecting science. Creating value.PagesServicesExpertise across the BD value chainPagesAbout JohnExperience behind the partnershipsPagesOur approachFrom strategy to signed agreementPagesOpportunitiesExplore assets for partneringPagesTrack recordPartnerships and downloadable deal summariesPagesStart a conversationDiscuss an opportunity with JohnPagesMy cross-border dealsJEA reference library on Google DriveTransactionsCross-border deal libraryJEA reference library on Google DriveTransactionsDLL3 ADCOncology · IND Filing · DLL3AssetsHER2 Biparatopic ADCOncology · Phase 3 · HER2AssetsFRα Biparatopic ADCOncology · IND Filing · FRαAssetsCYP11B2 InhibitorCardiovascular · IND Filing · CYP11B2AssetsENPP1 InhibitorCardiovascular · IND Approved · ENPP1AssetsB7-H3 ADCOncology · Phase 1 · B7-H3AssetsATM InhibitorOncology · Phase 1 · ATMAssetsKAT6 InhibitorOncology · Phase 1 · KAT6A / KAT6BAssetsEGFR-ADCOncology · Phase 3 · EGFRAssetsNovaRock × Bionyra (2026)Exclusive license agreement for NBL-023, a novel anti–IL-25 monoclonal antibody, granting worldwide rights outside Greater China.TransactionsNovaRock × LigaChemBio (2026)Global out-licensing agreement for an ADC candidate targeting a novel oncology antigen.TransactionsCSPC × Radiance Biopharma (2025)$1,240 million strategic partnership for ROR1-ADC (SYS6005).TransactionsCSPC × Cipla (2025)$1,065 million strategic partnership for an Irinotecan Liposomal Injection product.TransactionsNovaRock × LigaChemBio (2025)Two global out-licensing agreements for novel antibodies.Transactions

CONTEXT & LIMITATIONS

An informed starting point.

Information on this website supports an initial conversation. Review the original JEA disclaimer and the context for the asset library and transaction records.

JEA’s disclaimer

The existing JEA BizDev Consulting disclaimer is available in its original format.

Read the disclaimer (PDF)

Asset information

Asset descriptions preserve information from existing JEA materials, including historical development plans and sponsor-reported scientific data. Current development status, supporting data, rights, and availability should be confirmed directly with JEA.

Transaction information

Transaction announcements and deal summaries are historical reference materials. Headline transaction values may include contingent milestones and do not necessarily represent consideration already received.

Starting an engagement

Submitting an inquiry starts a conversation. Scope, fees, deliverables, and other engagement terms are agreed separately.